Malaria is a major cause of anaemia in tropical areas. Malaria infection causes haemolysis
of infected and uninfected erythrocytes and bone marrow dyserythropoiesis which …

Immunity to malaria has been linked to the availability and function of helper CD4+ T cells,
cytotoxic CD8+ T cells and γδ T cells that can respond to both the asymptomatic liver stage …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

Controlled human infection (CHI) trials, in which healthy volunteers are experimentally
infected, can accelerate the development of novel drugs and vaccines for infectious …

Sanaria Inc. has developed methods to manufacture, purify and cryopreserve aseptic
Plasmodium falciparum (Pf) sporozoites (SPZ), and is using this platform technology to …

We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI)
of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ)(PfSPZ …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …